论文部分内容阅读
目的研究奈达铂在术后2期非小细胞肺癌患者化疗中的作用。方法回顾性分析283名术后2期非小细胞肺癌患者术后化疗的临床资料。将患者分为奈达铂组和顺铂组。收集3级~4级的副反应资料、总生存率和无进展生存率。以Kaplan-Meier法进行生存分析。结果大多数患者病理类型为腺癌患者及非吸烟患者。在奈达铂组中,白细胞降低率、中性粒细胞降低率、血小板的降低率分别为27.0%、19.0%、10.3%,较顺铂组显著性降低,差异均有统计学意义(P<0.05)。2组的总生存率和无进展生存率差异无统计学意义(P>0.05)。多因素风险比例回归分析显示,尽管奈达铂可降低总的死亡风险(风险比例为0.975;95%CI:0.730~1.302;P=0.864)和提高无进展死亡风险(风险比例为1.084;95%CI:0.811~1.448;P=0.585),但差异无统计学意义。结论奈达铂的副作用明显低于顺铂。奈达铂在术后2期非小细胞肺癌化疗中的作用与顺铂相当,有望成为化疗药物。
Objective To study the role of Nedaplatin in the chemotherapy of two non-small cell lung cancer patients after operation. Methods The clinical data of 283 patients with postoperative chemotherapy of 2 stage non-small cell lung cancer were analyzed retrospectively. The patients were divided into nedaplatin group and cisplatin group. Collect grade 3 to 4 side effects data, overall survival and progression-free survival. Survival analysis with Kaplan-Meier method. Results Most of the pathological types of patients with adenocarcinoma and non-smoking patients. In the nedaplatin group, the rates of leukopenia, neutropenia and platelet reduction were 27.0%, 19.0% and 10.3%, respectively, which were significantly lower than those in cisplatin group (P < 0.05). There was no significant difference between the two groups in overall survival and progression-free survival (P> 0.05). Multivariate risk proportional regression analysis showed that although nedaplatin reduced the overall risk of death (hazard ratio 0.975; 95% CI 0.730-1.302; P = 0.864) and increased risk of progression-free death (hazard ratio 1.084; 95% CI: 0.811-1.448; P = 0.585), but the difference was not statistically significant. Conclusion The side effects of nedaplatin were significantly lower than that of cisplatin. Nedaplatin in postoperative 2 non-small cell lung cancer chemotherapy and cisplatin in the same role, is expected to become chemotherapy drugs.